VivoSim Labs (VIVS) · Deep analysis

Report previewVIVS.USReport date Last updated
← Back to reports
Report contents

At a glance

  • Business model: VivoSim Labs does not disclose what it sells, who pays, whether revenue recurs, or how concentrated customers are; FY2026 revenue rounds to zero at the reported precision. That gap blocks tests of pricing power and durability, and no specific advantage can be identified. The first detailed contract disclosure will matter more than any strategy statement.
  • Financial quality: Cash was about $10 million at September 30, 2026, and FY2026 operating cash use rounded to the same figure, leaving roughly four quarters of runway. Equity was near zero at March 31, 2026, debt rounds to zero, and funding depends on outside capital. With revenue near zero, the cash-flow statement is more informative than margins.
01

Business model

Business model: the revenue model is still the open question

VivoSim Labs (VIVS) is a small listed company, and the public record does not yet establish what it sells, who signs the check, or whether that check recurs. Those three facts decide most of what an investor needs next: gross margin, capital intensity, customer concentration, and how much of the revenue base survives a bad year. Without them, a claim about durability is a guess. The working judgment is that VivoSim is stage unproven with an undetermined business type, and the first substantive disclosure (an annual report with revenue detail, a named commercial contract, or a customer reference) will say more than any statement of strategy.

A name is not a revenue model

"Labs" in a corporate name signals where work happens, not who pays for it. Companies using the word sell per-study services, software licenses and funded research programs, and the economics of the three barely overlap. Per-study work ties revenue to booked orders and bench capacity: gross margin becomes a utilization number, working capital sits in receivables, and growth requires hiring and equipment before it requires demand. A license or subscription inverts that, with revenue that recurs, high incremental margin and cash spent upfront on sales. A sponsored-research or milestone model makes the company a supplier to someone else's program, paid in binary installments, with little pricing power of its own.

Contract structure separates these, and contract structure is observable even when revenue totals are not. A filing that describes per-project fees, multi-year licenses or milestone schedules settles the question faster than any growth rate.

ArchitectureWhat recursWhere capital goesMain fragility
Per-study servicesProject ordersBench capacity, staffUtilization, order backlog
Software or licenseSeats, subscriptionsSales and marketingChurn, slow procurement
Sponsored researchMilestonesR&D programDependence on one sponsor
The payer sets the bargaining power

Customer identity is the second unknown, and it drives more than concentration. If pharmaceutical or biotech sponsors pay, purchases run through slow procurement, contracts are often fixed-price, and the vendor absorbs the cost of a mispriced estimate; the sponsor also sets payment terms, so receivables can absorb cash the income statement says was earned. If the buyer is an individual researcher or a small lab, tickets are smaller, sales cycles shorter, and no single account can dictate terms. The two worlds produce very different revenue quality from the same headline number.

Geography is equally unsettled. A US listing says nothing about where revenue is earned, and a company can be listed in New York while selling entirely into Europe or Asia. Until a filing breaks out revenue by region, any assumption about end-market demand or reimbursement exposure is unsupported. The first geographic split is worth reading closely, because a single-region business carries regulatory and currency exposure that the listing venue hides.

Stage and funding are part of the model

An unproven-stage company funds operations from outside capital, and the financing pattern reveals the model. Service work can partly self-fund through customer prepayments and receivables, while a platform build consumes cash well before revenue arrives. Watch how the company pays for capacity: leased lab space and contract staff point to a variable-cost services model that can shrink in a slow year, whereas owned facilities and a large internal R&D staff point to fixed costs that must be filled or written down. Neither is wrong, but they fail differently, and only one of them protects cash when demand slips.

What would settle it

The read shifts from "unidentified" to "assessable" once a filing shows revenue by contract type, the share held by the largest customers, and typical contract length. Two patterns would move it in opposite directions. Several unrelated customers on multi-year terms would point to a platform with a recurring base. One sponsor funding a defined program would point to a research supplier whose revenue ends when the program does, and whose renewal risk sits with a single counterparty. Until one of those appears, the most informative event VivoSim can produce is its first detailed contract disclosure, and the questions below track exactly that.

Questions worth following

  • Can VivoSim Labs turn pilot work into recurring contracts?

    Whether early engagements repeat determines gross margin structure, sales efficiency and how much revenue survives the loss of a single account. A pilot that stays a pilot leaves the company dependent on new business each period, which changes both the growth profile and the cash cycle.

  • Will VivoSim Labs' largest customer renew on comparable terms?

    Concentration decides bargaining power. A buyer accounting for most revenue can set price, scope and payment timing, so the renewal outcome shows whether VivoSim holds pricing power or merely fills capacity, and it fixes the revenue base for the following year.

02

Financial quality

Financial quality: the balance sheet sets the clock

VivoSim Labs is a pre-commercial biotechnology company, and its financials are too small for most ratios to carry much information. Very weak is the right grade, but not because a loss exists. There is almost no revenue to grade, the company spends roughly its entire cash balance to operate each year, and it closed FY2026 (March 31, 2026) with equity near zero. Funding timing, not margin, is what determines the next chapter.

Cash is the binding constraint. At September 30, 2026, the end of the second quarter of FY2027, cash rounded to about $10 million. Operating cash use for the full FY2026 year rounded to the same $10 million. That pairing implies roughly four quarters of runway before another raise, and the reporting grid of $10 million means either figure could be several million off. Free cash flow has matched operating cash flow in every year shown because capital spending is too small to separate; this is a business whose cash goes to people and programs, not equipment. With free cash flow negative in every period, distributions are not a factor.

A revenue base too small for margins to mean anything

FY2026 revenue rounds to zero at the reported dollar granularity. Margin percentages are the only usable scale indicator: a net margin of -10,567% puts the cost base near 100 times revenue, which implies revenue near $0.1 million if the rounded loss is taken at face value. Gross margin held at 100% from FY2022 through FY2026, an artifact of having no meaningful cost of revenue rather than a sign of pricing power.

MetricFY2022FY2023FY2024FY2025FY2026Q ended 9/30/26Assessment
Revenue (USD mn)0.00.00.00.00.00.0Very weak
Gross margin (%)100.0100.0100.096.5100.0-6,502.0Very weak
Net margin (%)-763.2-4,664.6-13,459.6-1,727.8-10,567.2-931.4Very weak
ROE (%)-33.0-75.8-155.0-35.3-294.8-19.4Very weak
ROA (%)-31.3-64.4-110.1-23.7-125.6-6.9Very weak
Asset turnover (x)0.0410.0140.0080.0140.0120.007Very weak
Receivables turnover (x)n.d.2.431.184.570.240.09Very weak
Current ratio (x)21.354.642.123.252.383.50Adequate
Quick ratio (x)21.354.641.963.252.383.49Adequate
Liabilities/assets (%)9.324.543.328.4Not disclosedNot disclosedWeak
Operating cash flow (USD bn)-0.01-0.01-0.01-0.01-0.01-0.00Very weak
Free cash flow (USD bn)-0.01-0.01-0.01-0.01-0.01-0.00Very weak
Cash (USD bn)0.030.010.000.010.010.01Weak
Total assets (USD bn)0.030.020.010.010.010.01Very weak
Total equity (USD bn)0.030.010.000.01-0.000.01Very weak

Fiscal years end March 31. *Single quarter; not comparable with annual figures. Dollar cells are as reported to two decimals in billions, so "0.01" spans roughly $5–15 million.

The September 2026 quarter breaks the gross-margin pattern. A reading of -6,502% means cost of revenue exceeded revenue, so VivoSim booked a gross loss. One quarter cannot establish whether that was a write-off, a one-time delivery cost, or a permanent step up. It does mean the 100% history is not a cushion, and it undercuts any projection that assumes added revenue arrives at a high gross margin.

Negative equity turns ROE into an arithmetic accident

ROE moved from -294.8% in FY2026 to a positive 77.7% in the June 2026 quarter, a period in which VivoSim lost money. The sign flip comes from equity sitting at roughly zero and briefly below it: divide a small loss by nearly nothing and the ratio explodes, then reverses when the denominator moves again. ROE deserves no weight. ROA, at -31% in FY2022, -64% in FY2023, -110% in FY2024, -24% in FY2025 and -126% in FY2026, is the more honest measure, and it shows deeply negative, unstable returns on a shrinking asset base: asset turnover slid from 0.041 to 0.012 in five years.

The equity path carries the real information. Total equity fell from about $30 million at March 31, 2022, to about $10 million a year later, then to roughly zero at March 31, 2026, before rounding back to about $10 million at September 30, 2026. Cash and equity rising together usually signal a share sale, yet financing cash flow for that quarter rounds to zero while investing cash flow shows a like-sized inflow. Those figures do not identify the source; the 10-Q should.

Leverage is not the risk. Long-term and short-term debt both round to zero, and liabilities-to-assets ran 9.3%, 24.5%, 43.3% and 28.4% from FY2022 to FY2025 (not disclosed for FY2026, when equity sat near zero). Pressure comes from equity depletion instead.

Liquidity ratios compare very small numbers

Receivable turnover fell from 4.57 in FY2025 to 0.24 in FY2026 and 0.09 in the September 2026 quarter. With revenue near $0.1 million, one unpaid grant or collaboration invoice can swing that ratio, so the decline is not by itself evidence of collection trouble. It does show receivables are large relative to sales, which weakens the working-capital ratios as signals. A current ratio of 3.50 and quick ratio of 3.49 look comfortable; the same current ratio was 21.4 in FY2022 and 1.70 in the June 2026 quarter. That whipsaw tracks financing events, not operating improvement.

MetricQ ended 6/30/259/30/2512/31/253/31/266/30/269/30/26AssessmentTrend
Revenue (USD mn)0.00.00.00.00.00.0Very weakFlat at nil
Gross margin (%)100.0100.0100.0100.0100.0-6,502.0Very weakDeteriorating
Net margin (%)-7,683.8-9,089.3-10,350.0-14,410.0-7,433.3-931.4Very weakVolatile
Net income (USD bn)-0.00-0.00-0.00-0.01-0.00-0.00Very weakStable loss
Total assets (USD bn)0.010.010.010.010.000.01Very weakFlat
Total liabilities (USD bn)0.000.000.000.010.010.00WeakVolatile
Cash (USD bn)0.010.010.000.010.000.01WeakVolatile
Operating cash flow (USD bn)-0.00-0.00-0.00-0.00-0.00-0.00Very weakPersistently negative
Financing cash flow (USD bn)0.000.00-0.000.00-0.000.00WeakErratic
Current ratio (x)4.523.102.442.381.703.50AdequateVolatile

Net PP&E is not broken out in any period, and revenue is not reported above the rounding threshold; fiscal quarters end on those calendar dates.

What to check next

Three items decide how the finances read a year from now. First, runway and the wording of the FY2026 10-K on going concern, plus whether the September 2026 balance sheet improvement came from share sales, which would surface in share count and per-share losses before it surfaces in net income. Second, the source of the September 2026 gross loss: a recurring cost step would make every extra dollar of revenue less valuable, while a one-time charge would not. Third, the size and counterparty behind a 0.09 receivables turnover, because at this revenue level a single uncollected invoice can exceed a quarter of sales.

Questions worth following

  • Can VivoSim reach repeat revenue before it needs new equity?

    Runway decides whether VivoSim can wait for qualification and repeat orders or must raise first. A raise before recurring revenue arrives happens at whatever terms the market offers, and the per-share cost of that dilution persists even if the business later succeeds.

  • Can VivoSim grow revenue to cover a meaningful share of its costs?

    A FY2026 net margin of -10,567% implies a cost base near 100 times revenue. Sales must multiply many times before operating leverage narrows the loss, and the answer separates a product business from a research program permanently dependent on capital markets.

Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.

Go beyond the preview

Continue reading the full report

  1. Key risksWhat could break the investment case
  2. Valuation and margin of safetyWhat the current price assumes, and how much room for error it leaves
  3. SummaryOur overall judgement and what to watch next

Free to sign up · 20 research points · unlocking this report uses 10

20 points cover 2 full reports. No card needed.

Research reflects its generation date. Preview the first two modules.

More on VivoSim Labs, Inc.